Showing posts with label metformin. Show all posts
Showing posts with label metformin. Show all posts

Friday, February 1, 2013

Diabetes Drug May Improve Survival in Patients With Ovarian Cancer


Diabetes Drug May Improve Survival in Patients With Ovarian Cancer


Lauren M. Green
Published Online: Wednesday, January 30, 2013 

The oral diabetic medication metformin may help improve survival in patients with ovarian cancer, according to the results of a retrospective case-control study from the Mayo Clinic in Rochester, Minnesota.

Previous studies have shown promise for metformin as an anticancer compound. For this study, researchers used Mayo Clinic hospital records to identify patients with ovarian cancer who also received metformin for a minimum of 1 year at or after their cancer diagnosis (mean duration = 2.3 years; range, 1-11 years). Duration of metformin therapy prior to their cancer diagnosis was unknown.

The study’s ovarian cancer cohort comprised women with ovarian cancer who were also taking metformin (n = 72) and a randomly selected control group of patients with ovarian cancer who did not receive metformin (n = 143). Median disease-specific survival (DSS) for the entire group was 5.5 years. For the control group, the 5-year survival rate was 44%, whereas the survival rate for patients on metformin was 73% (P = .002).

Because epithelial ovarian cancer (EOC) accounts for most ovarian cancer mortality, the researchers identified a subset of patients with EOC from the initial cohort who had received metformin (n = 61) and compared these cases with a control group of patients with ovarian cancer who had not received metformin (n =178). Variables such as age, disease stage, histology, and receipt of platinum- versus non-platinum–based chemotherapy were similar between the two groups, which together comprised the EOC cohort (N = 239).

For the entire EOC cohort, the 5-year DSS rate was 52%. For the subset of EOC cases taking metformin, the DSS rate was significantly better than DSS in the control group: 67% versus 47%, respectively (P = .006). The researchers found that metformin was an independent predictor of survival, even after adjusting for body mass index, tumor grade, histology, surgical cytoreduction, disease stage, and chemotherapy (hazard ratio = 2.2; 95% CI, 1.2-3.8; P = .007).

When the EOC cohort was compared with a diabetic control group of patients with EOC whose diabetes was being treated with insulin or medications other than metformin (n = 103), 5-year DSS was lower for the diabetic control group (40%) as compared with the EOC cohort and nondiabetic controls. In this analysis, researchers also looked at 5-year DSS associated with specific antidiabetic medications. Metformin use was associated with a higher DSS rate (67%) than insulin (43%) and other antidiabetic medications (34%; P = .004).

The researchers noted that their findings are consistent with an earlier University of Chicago study reported in the January 2012 issue of Obstetrics & Gynecology, which found an association between metformin and improved recurrence-free survival in patients with ovarian cancer.

“Our study demonstrated improved survival in women with ovarian cancer who were also taking metformin,” co-lead author Sanjeev Kumar, MBBS, a fellow in Gynecologic Oncology at the Mayo Clinic, said in a statement. “Although causation could not be assessed by our retrospective study, metformin nevertheless is a strong contender for further clinical studies in ovarian cancer,” the researchers concluded.

Thursday, December 20, 2012

Diabetes drug may treat ovarian cancer


Diabetes drug may treat ovarian cancer


Patients with ovarian cancer who took the drug metformin for diabetes had a better survival rate than patients who did not take the drug. These findings may play an important role for researchers as they study the effectiveness of existing medications in treating different or new diseases.
Metformin is widely prescribed for managing diabetes, and previous research by others has shown its promise for other cancers. This study adds ovarian cancer to the list.
The research team compared the survival of 61 patients with ovarian cancer who were taking metformin and 178 patients who were not taking metformin. After 5 years, 67% of the patients who took metformin were still surviving, compared with 47% of those who did not take the medication. When the researchers analyzed factors such as the patients' body mass index, the severity of the cancer, type of chemotherapy, and quality of surgery, the patients taking metformin were nearly four times more likely to survive compared with those not taking the medication.
“Our study demonstrated improved survival in women with ovarian cancer that were taking metformin,” says coauthor Sanjeev Kumar, MBBS, a Mayo Clinic gynecologic oncology fellow. “The results are encouraging, but as with any retrospective study, many factors cannot be controlled for us to say if there is a direct cause and effect. Rather, this is further human evidence for a potential beneficial effect of a commonly used drug which is relatively safe in humans. These findings should provide impetus for prospective clinical trials in ovarian cancer.”
The researchers explained that the results may pave the way for using metformin in large-scale randomized trials of ovarian cancer. The high rate of mortality in ovarian cancer indicates the great need to develop new therapies. Metformin may potentially be one of those options